Skip Navigation


JAC Advance Access originally published online on December 23, 2004
Journal of Antimicrobial Chemotherapy 2005 55(2):139-142; doi:10.1093/jac/dkh533
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/2/139    most recent
dkh533v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Akuta, N.
Right arrow Articles by Kumada, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akuta, N.
Right arrow Articles by Kumada, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.55 no.2 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved

Leading article

Influence of hepatitis B virus genotypes on the response to antiviral therapies

Norio Akuta* and Hiromitsu Kumada

Department of Gastroenterology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-0001, Japan

* Corresponding author. Tel: +81-44-877-5111; Fax: +81-44-860-1623; Email: akuta-gi{at}umin.ac.jp

Hepatitis B virus (HBV) has been classified into eight genotypes (A–H) based on genome sequence divergence. Genotypes of HBV have distinct geographical distributions, and two genotypes account for most HBV worldwide. Hepatitis B e antigen expression lasts longer and liver disease is more severe with graver outcomes in carriers of genotype C than B in Asia. Accumulating lines of evidence indicate a better response to interferon and lamivudine in patients with chronic hepatitis B who are infected with genotype B rather than C. The therapeutic response may differ, however, in patients infected with HBV of the same genotype. For example, the response to lamivudine is poorer in patients infected with subtype Ba, which contains a recombination with genotype C, than in those with subtype Bj without such a recombination. Influence of genotypes on therapeutic response needs to be examined in patients infected with the other genotypes, particularly in those with genotype A or D infection.

Keywords: chronic hepatitis , genotypes , hepatitis B e antigen , hepatitis B virus , interferon , lamivudine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
L. C. J. Alcantara, S. Cassol, P. Libin, K. Deforche, O. G. Pybus, M. Van Ranst, B. Galvao-Castro, A.-M. Vandamme, and T. de Oliveira
A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences
Nucleic Acids Res., July 1, 2009; 37(suppl_2): W634 - W642.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
M. A. Purdy, A. C. Gonzales, Z. Dimitrova, and Y. Khudyakov
Supragenotypic groups of the hepatitis B virus genome
J. Gen. Virol., May 1, 2008; 89(5): 1179 - 1183.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
C. Osiowy, J.-P. Villeneuve, E. J. Heathcote, E. Giles, and J. Borlang
Detection of rtN236T and rtA181V/T Mutations Associated with Resistance to Adefovir Dipivoxil in Samples from Patients with Chronic Hepatitis B Virus Infection by the INNO-LiPA HBV DR Line Probe Assay (Version 2).
J. Clin. Microbiol., June 1, 2006; 44(6): 1994 - 1997.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
P. Simmonds and S. Midgley
Recombination in the Genesis and Evolution of Hepatitis B Virus Genotypes
J. Virol., December 15, 2005; 79(24): 15467 - 15476.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.